login

Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease

Annals of NeurologyPublished 1 April 2001
Fabio Blandini, Giuseppe Nappi, J. Timothy Greenamyre
Citations62
SJR quartileQ1
SJR score3.74
SNIP2.26

TL;DR

It is concluded that pharmacological modulation of subthalamic activity may have both symptomatic and neuroprotective effects in Parkinson's disease.

Abstract

Using permanent cannulas connected to subcutaneous pumps, we infused selective glutamate antagonists into the subthalamic nucleus of rats. Pumps were implanted immediately after the intrastriatal injection of 6-hydroxydopamine and delivered micro-quantities of the Nmethyl-D-aspartate antagonist MK-801 or the alpha-amino-3-hydroxy-5-methylisoxazole antagonist NBQX for 4 weeks. Subthalamic infusion of MK-801, but not of NBQX, prevented the basal ganglia metabolic changes and motor abnormalities caused by nigrostriatal lesion. Animals treated with MK-801 also exhibited marked reduction of nigral cell loss. We conclude that pharmacological modulation of subthalamic activity may have both symptomatic and neuroprotective effects in Parkinson's disease.

Keywords

MedicineNeuroscience